Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares ...

Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...

Both stocks should deliver excellent returns to investors patient enough to hold through volatility. Equity markets started ...

Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. VRTX ...

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve ...

Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...

Vertex Pharmaceuticals Inc.’s new non-opioid ... The medication, called Journavx, was approved in the United States in January. The financial success of new drugs largely depends on how they ...

Vertex Pharmaceuticals (VRTX ... retain it for some time to see if its CF sales continue to rise and how the Journavx and Alyftrek launch progress. Fear, uncertainty, and doubt have become ...

Vertex Pharmaceuticals (NASDAQ ... company’s recent approval of Alyftrek for CF and the anticipated launch of Journavx for acute pain management mark important milestones in its growth strategy.